{"product_id":"aspirin-and-cancer-prevention-what-patients-need-to-know-about-the-evidence-risks-and-new-research","title":"Aspirin and Cancer Prevention: What Patients Need to Know About the Evidence, Risks, and New Research","description":"\u003cp\u003eDaily aspirin use has emerged as one of the most promising strategies for cancer prevention, with more than 100 observational studies and multiple randomized controlled trials demonstrating significant reductions in cancer risk — particularly for colorectal cancer. While the evidence is strongest for people with Lynch syndrome (a hereditary condition that dramatically increases cancer risk), researchers are now launching a major new trial called CaPP3 to determine the optimal aspirin dose for cancer prevention, testing 100mg, 300mg, and 600mg daily doses in 3,000 gene carriers. This article explains the science behind aspirin's anti-cancer effects, the risks patients should understand, and what these findings mean for cancer prevention.\u003c\/p\u003e\n\n\u003ch1\u003eAspirin and Cancer Prevention: What Patients Need to Know About the Evidence, Risks, and New Research\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: How Aspirin Became a Cancer Prevention Candidate\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#observational\"\u003eEvidence from Large Population Studies\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#capp2\"\u003eThe CAPP2 Trial: Proof in High-Risk Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#womens\"\u003eThe Women's Health Study and Other Clinical Trials\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#capp3\"\u003eThe CaPP3 Trial: Finding the Right Dose\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#risks\"\u003eUnderstanding the Risks of Daily Aspirin\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#balance\"\u003eBalancing Benefits and Risks: A Real-World Example\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications and Recommendations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Current Evidence\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eMore than 100 observational studies show long-term aspirin users have roughly 50% lower colorectal cancer risk, but randomized trials provide weaker evidence.\u003c\/li\u003e\n\u003cli\u003eIn the CAPP2 trial of 1,009 Lynch syndrome carriers, 600 mg aspirin daily for at least 2 years cut colorectal cancer by over 60%.\u003c\/li\u003e\n\u003cli\u003eAspirin's cancer prevention takes 4–10 years to appear, so short-term trials may miss its full benefit.\u003c\/li\u003e\n\u003cli\u003eDaily aspirin raises bleeding risk: about 1 extra gastrointestinal bleed per 1,000 people per year and 1 in 10,000 for intracranial hemorrhage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: How Aspirin Became a Cancer Prevention Candidate\u003c\/h2\u003e\n\n\u003cp\u003eThe story of aspirin and cancer prevention began with a simple observation. In 1988, Kune and colleagues conducted a case-control study in Melbourne, Australia, and found something striking: people who regularly used non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin were significantly less likely to develop colorectal cancer (cancer of the colon or rectum).\u003c\/p\u003e\n\n\u003cp\u003eThat single study opened the floodgates. With just one exception — a study of elderly Californians — more than 100 observational and epidemiological studies since then have confirmed the same finding: long-term regular aspirin users have a roughly 50% reduction in colorectal cancer risk after prolonged use. These studies tracked large populations over many years, comparing cancer rates among aspirin users versus non-users.\u003c\/p\u003e\n\n\u003cp\u003eThe research also revealed an intriguing pattern. Aspirin's protective effect doesn't appear immediately. Instead, the benefit emerges gradually over years of use, suggesting aspirin works not by treating existing cancers but by preventing the earliest stages of cancer development. This delayed effect is a recurring theme in the research, with protection typically becoming apparent 4 to 10 years after starting aspirin.\u003c\/p\u003e\n\n\u003ch2 id=\"observational\"\u003eEvidence from Large Population Studies\u003c\/h2\u003e\n\n\u003cp\u003eThe observational evidence is backed up by several types of clinical research. A meta-analysis by Cole and colleagues in 2009 combined the results of five adenoma prevention trials — studies that looked at whether aspirin could prevent adenomas (precancerous polyps) in the colon. The analysis found that aspirin reduced the number of adenomas by approximately 19%. The selective COX-2 inhibitors (a related class of anti-inflammatory drugs) showed a similar effect, but trials were halted after these drugs were linked to excess cardiovascular events (heart attacks and strokes).\u003c\/p\u003e\n\n\u003cp\u003ePerhaps the most influential evidence came from a series of papers by Rothwell and colleagues, published in The Lancet. The researchers re-examined data from early cardiovascular prevention trials — studies originally designed to test aspirin's heart-protective effects — by looking at national cancer registry records. Among 25,570 patients, there were 674 cancer-related deaths. Those who had been randomly assigned to take aspirin had 21% fewer cancer deaths compared to those assigned to placebo, with the effect beginning to appear about five years after the trials started.\u003c\/p\u003e\n\n\u003cp\u003eNotably, this effect did not appear to be dose-related. Early cardiovascular trials used aspirin doses up to 1,200mg per day, but as research showed that the anti-platelet effect could be achieved with much smaller, safer doses, the standard was progressively reduced to 75–100mg daily. The fact that both high and low doses seemed to provide cancer protection raised an important question: could the low doses already used for heart health also prevent cancer?\u003c\/p\u003e\n\n\u003ch2 id=\"capp2\"\u003eThe CAPP2 Trial: Proof in High-Risk Patients\u003c\/h2\u003e\n\n\u003cp\u003eWhile observational studies are suggestive, the gold standard of medical evidence is the randomized controlled trial (RCT), where patients are randomly assigned to receive either the treatment or a placebo. The first major RCT with cancer as a primary endpoint was the CAPP2 trial, which targeted a very specific high-risk group: carriers of Lynch syndrome.\u003c\/p\u003e\n\n\u003cp\u003eLynch syndrome, formerly known as Hereditary Non-Polyposis Colon Cancer (HNPCC), is an inherited condition caused by a mutation in one of the mismatch repair genes. These genes normally fix errors that occur when DNA is copied during cell division. When they don't work properly, damaged cells can accumulate and eventually become cancerous. Approximately half of people with this autosomal dominant disorder develop a solid tumor, typically between ages 35 and 65. Cancers occur most commonly in the colorectum (colon and rectum) or endometrium (lining of the uterus), but can also affect other parts of the gastrointestinal tract, kidney, gallbladder, skin, and brain.\u003c\/p\u003e\n\n\u003cp\u003eCAPP2 enrolled 1,009 carriers of a mismatch repair gene defect. Participants were randomly assigned to receive 600mg of enteric-coated aspirin daily, 30 grams of resistant dietary starch, both, or neither — for up to four years, with follow-up extending to 10 years. At the end of the treatment period, there was no measurable effect on adenoma formation in any treatment group.\u003c\/p\u003e\n\n\u003cp\u003eBut the story didn't end there. At a mean follow-up of five years, researchers analyzed the data and found no benefit from resistant starch, but something remarkable in the aspirin group. Using a per-protocol analysis — which focuses specifically on participants who complied with the primary treatment aim and took aspirin for at least two years (confirmed by tablet counts) — there was a greater than 60% reduction in colorectal cancer. The incident rate ratio was 0.37 (95% confidence interval 0.18–0.78, p=0.008). In plain language, this means the aspirin group had 63% fewer colorectal cancers than the placebo group, a result that could not be attributed to chance (p=0.008 means there is only a 0.8% probability the finding was due to random variation).\u003c\/p\u003e\n\n\u003cp\u003eStrikingly, the aspirin also reduced other Lynch syndrome-associated cancers, such as endometrial cancer, by a comparable amount. The protective effect became apparent from about four years after starting the trial. By 2013, the data showed 45 new colorectal cancers among the 434 participants who had received placebo, compared with just 25 cancers among the 427 participants who had received 600mg aspirin daily.\u003c\/p\u003e\n\n\u003cp\u003eThese findings were highly significant for Lynch syndrome carriers. Because their cancer risk remains very high despite regular colonoscopy surveillance, the researchers concluded that all gene carriers should be made aware of this effect. Steps are now being taken to have aspirin's anti-cancer effect officially recognized as an indication for routine prescription.\u003c\/p\u003e\n\n\u003ch2 id=\"womens\"\u003eThe Women's Health Study and Other Clinical Trials\u003c\/h2\u003e\n\n\u003cp\u003eNot all randomized trials found an immediate benefit. The Women's Health Study, one of the largest prevention trials ever conducted, gave 39,876 American women aged 45 and older either 100mg of aspirin on alternate days or a placebo for a median of 10 years. At the end of the trial, there was no detectable effect on cancer — one of the trial's primary endpoints.\u003c\/p\u003e\n\n\u003cp\u003eHowever, long-term follow-up told a different story. When researchers tracked these women for up to 18 years, they found an 18% reduction in colorectal cancers among the aspirin group (p=0.024), with the effect only beginning to emerge 10 years after aspirin was started. This finding reinforces the notion that aspirin's cancer-preventive effects are slow to manifest and that short-term trials may miss benefits that appear only with extended follow-up.\u003c\/p\u003e\n\n\u003cp\u003eAnother randomized trial, the Physicians' Health Study, tested 325mg of aspirin on alternate days in American male physicians. Reanalysis of the data and long-term review found no effect on cancer, adding nuance to the picture — and raising questions about whether dose, timing, or sex differences matter in aspirin's cancer-preventive effects.\u003c\/p\u003e\n\n\u003cp\u003eThe CAPP2 trial remains the only randomized controlled trial to date that used cancer as a primary endpoint and demonstrated a statistically significant benefit — a major reason why this study is considered such an important milestone.\u003c\/p\u003e\n\n\u003ch2 id=\"capp3\"\u003eThe CaPP3 Trial: Finding the Right Dose\u003c\/h2\u003e\n\n\u003cp\u003eThe success of CAPP2 raised an urgent practical question: which dose of aspirin should be recommended? The study used 600mg daily, but this is higher than the 75–100mg typically prescribed for cardiovascular protection. Lower doses are associated with fewer side effects, but whether they provide equal cancer protection in Lynch syndrome is unknown.\u003c\/p\u003e\n\n\u003cp\u003eTo answer this question, the CaPP3 trial was launched. The trial will enroll 3,000 carriers of mismatch repair gene defects who are at risk of Lynch syndrome. Unlike a traditional randomized controlled trial, there is no placebo arm — every participant receives aspirin. Instead, participants are randomly assigned to one of three doses: 600mg, 300mg, or 100mg of enteric-coated aspirin daily. For the first two years, the dose assignment is blinded (neither the participant nor the researchers know which dose is being taken). After that, all participants switch to open-label 100mg enteric-coated aspirin daily and are followed for a minimum of five years.\u003c\/p\u003e\n\n\u003cp\u003eThis is a non-inferiority trial, designed to test whether the lower doses are no worse than the highest dose. Using the cancer rates seen in CAPP2 and comparing all Lynch syndrome cancers (not just colorectal), the trial is powered to detect a relative benefit of the highest dose of 1.5 — in other words, for every three cancers prevented by 600mg daily, there would be at least two fewer in the 100mg group. Results were expected around 2020.\u003c\/p\u003e\n\n\u003cp\u003eThe trial also has a biological rationale. While accepted wisdom holds that 75–100mg of aspirin is only effective against platelets (the blood cells involved in clotting), some researchers note that wild green plants naturally release salicylates (the chemical family to which aspirin belongs) to trigger apoptosis — programmed cell death — when infection develops. This \"scorched earth policy\" limits the spread of infection. During human evolution, our natural diet would have contained measurable amounts of salicylate, but these are largely lost in modern farmed foods. This observation has led some scientists to speculate that aspirin may be acting as an essential nutrient, with a pro-apoptotic effect or enhanced immune surveillance explaining aspirin's delayed impact on cancer — the destruction of damaged stem cells would deplete precancerous cells before they can develop into tumors.\u003c\/p\u003e\n\n\u003ch2 id=\"risks\"\u003eUnderstanding the Risks of Daily Aspirin\u003c\/h2\u003e\n\n\u003cp\u003eNo prevention strategy is without risks, and aspirin is no exception. The main concerns are bleeding-related side effects, which patients should understand before starting daily aspirin therapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGastrointestinal bleeding and ulcers.\u003c\/strong\u003e Daily aspirin is associated with a 0.1% excess risk (approximately 1 additional case per 1,000 people per year) of gastric ulcers and gastrointestinal (GI) bleeding. The risk tends to be higher with higher doses and in older age. Importantly, the risk is 2 to 3 times higher in people infected with \u003cem\u003eHelicobacter pylori\u003c\/em\u003e — a common stomach bacterium. Many authorities recommend testing for and eradicating H. pylori infection in anyone contemplating regular aspirin use. The bleeding risk can also be reduced by regular use of a proton pump inhibitor (a type of acid-reducing medication), which offers additional protection at limited cost.\u003c\/p\u003e\n\n\u003cp\u003eData from CAPP2 itself illustrate this point. Among 861 people treated for up to four years, there were 11 significant GI bleeds or ulcers requiring hospital treatment in the 600mg aspirin group, compared with 9 in the placebo group — a non-significant excess. This is consistent with the large meta-analyses showing that side effects are most often seen in the elderly.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntracranial hemorrhage.\u003c\/strong\u003e There is also a 0.01% excess (1 in 10,000) of intracranial hemorrhage (bleeding inside the skull) per year of aspirin use. While rarely fatal, these bleeds can be highly debilitating. The protective effect of aspirin against the more common thrombotic stroke (stroke caused by a blood clot) offers statistical comfort, but a bleed causing disability in an otherwise healthy person is very distressing.\u003c\/p\u003e\n\n\u003cp\u003eHypertension (high blood pressure) is a major risk factor for hemorrhagic stroke. In the Antithrombotic Trialists' (ATT) Collaboration overview — a massive meta-analysis of individual participant data from randomized trials — there was a doubling of cerebral hemorrhage for each 20 mmHg rise in blood pressure (relative risk 2.18; 95% confidence interval: 1.65–2.87). By contrast, the HOT trial, which combined regular blood-pressure-lowering treatment with low-dose aspirin, found no evidence of any increase in hemorrhagic strokes associated with aspirin: there were 19 hemorrhagic strokes (7 fatal) among 9,399 subjects randomized to aspirin, compared with 20 (8 fatal) among 9,391 subjects on placebo. Blood pressure monitoring is therefore advisable, and active treatment of elevated blood pressure is appropriate.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOther bleeding risks.\u003c\/strong\u003e Bleeding outside the GI tract is related to platelet inhibition (the blood-thinning effect of aspirin) and is not dose-related. Occasional blood counts are helpful to detect asymptomatic blood loss — bleeding that occurs without noticeable symptoms — which can lead to anemia over time.\u003c\/p\u003e\n\n\u003cp\u003eSide effects are most common in people over 65 years of age and possibly in those with increased blood pressure. There is a trend toward higher bleeding rates with higher aspirin doses, though it should be noted that the traditional analgesic (pain-relieving) dose of aspirin was 300mg three times daily (900mg total per day), making even the highest dose in CaPP3 (600mg) a sub-analgesic, or \"low,\" dose. Nevertheless, the perception of 600mg as a \"high dose\" may limit its routine adoption by patients.\u003c\/p\u003e\n\n\u003ch2 id=\"balance\"\u003eBalancing Benefits and Risks: A Real-World Example\u003c\/h2\u003e\n\n\u003cp\u003eTo put the risks in perspective, the fact sheet provides a powerful comparison using real-world numbers from the United Kingdom. There are more than 10,000 adults over age 35 in the UK with Lynch syndrome. In the next 10 years, approximately 2,000 of these individuals will develop a cancer despite current surveillance. Allowing for aspirin's delayed effect, daily aspirin for five years would reduce that number by at least 250 cancers.\u003c\/p\u003e\n\n\u003cp\u003eWhat would the cost of that benefit be? Based on the risk figures above:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAround 50 extra gastrointestinal bleeds\u003c\/li\u003e\n  \u003cli\u003eFewer than 5 intracranial (brain) bleeds\u003c\/li\u003e\n  \u003cli\u003eFatality would be exceptional\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNow consider what those same 10,000 high-risk individuals will experience under current best-practice care: at least 50,000 colonoscopies. Based on the 2011 UK national colonoscopy audit, this will produce approximately 125 bleeds requiring blood transfusion and 20 emergency repairs of bowel perforation. Extrapolating from a large-scale Canadian study, there could be at least 3 deaths from these procedures.\u003c\/p\u003e\n\n\u003cp\u003eIn other words, taking daily aspirin carries risks comparable in both number and severity to the risks of regular colonoscopy screening — the current standard of care. The adverse effects and probable benefits of regular aspirin are comparable to, and potentially more favorable than, the risks of doing nothing beyond colonoscopy surveillance. Given that people with Lynch syndrome face such high cancer risk despite regular colonoscopy, this comparison is highly relevant.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications and Recommendations\u003c\/h2\u003e\n\n\u003cp\u003eThere is expert consensus that aspirin should be recommended to individuals at high risk of cancer, particularly those with Lynch syndrome. However, there is ongoing debate about the optimal dose and the risk-benefit ratio for the general population. Key points for patients include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLynch syndrome carriers:\u003c\/strong\u003e Given the very high cancer risk among Lynch syndrome carriers — despite regular colonoscopy — all gene carriers should be made aware of the highly significant effect found in CAPP2. Daily aspirin should be discussed with their healthcare provider.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDose considerations:\u003c\/strong\u003e While the CAPP2 trial used 600mg daily, lower doses (75–100mg) are currently used for cardiovascular prevention. The CaPP3 trial is designed to determine whether these lower doses are equally effective for cancer prevention. Meanwhile, low-dose aspirin can be recommended to high-risk individuals not taking part in the trial.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHelicobacter pylori testing:\u003c\/strong\u003e Because the frequency of GI bleeding is 2 to 3 times higher in those infected with H. pylori, testing for and treating this infection before starting regular aspirin is advisable.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStomach protection:\u003c\/strong\u003e Regular use of a proton pump inhibitor can substantially reduce the risk of gastrointestinal ulcers and bleeding.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBlood pressure monitoring:\u003c\/strong\u003e Because hypertension increases the risk of hemorrhagic stroke, blood pressure monitoring is advisable, and active intervention is appropriate if blood pressure is elevated.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonitoring:\u003c\/strong\u003e Occasional blood counts are helpful to detect asymptomatic blood loss.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe results of the CaPP3 trial will help inform this debate and will also be relevant to the general population. Colorectal cancer is now the second most common cancer, and around 1 in 6 sporadic (non-hereditary) cases share the same molecular mechanism of mismatch repair deficiency seen in Lynch syndrome. This means that insights gained from studying aspirin in this high-risk population may have broader applications for cancer prevention in everyone.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Current Evidence\u003c\/h2\u003e\n\n\u003cp\u003eWhile the evidence for aspirin's cancer-preventive effects is compelling, several limitations should be acknowledged:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDelayed benefits:\u003c\/strong\u003e The beneficial effects of aspirin on cancer take years to emerge — at least 4 to 5 years in CAPP2 and up to 10 years in the Women's Health Study. Short-term trials may miss real benefits.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInconsistent findings:\u003c\/strong\u003e Not all trials have shown a benefit. The Physicians' Health Study found no effect on cancer, and the initial results of the Women's Health Study (at trial end) also showed no effect. The reasons for these discrepancies are not fully understood but may relate to dose, timing, study population, or follow-up duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOptimal dose unknown:\u003c\/strong\u003e The optimal aspirin dose for cancer prevention remains unknown. The CaPP3 trial is designed to answer this question, but until results are available, recommendations must be based on extrapolation from existing data.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRisk-benefit ratio in the general population:\u003c\/strong\u003e While the benefits of aspirin for Lynch syndrome carriers clearly outweigh the risks, the balance is less certain for people at average cancer risk. The risk of bleeding and intracranial hemorrhage, while small, must be weighed against the absolute reduction in cancer risk, which varies depending on a person's baseline risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGeneralizability:\u003c\/strong\u003e The strongest evidence comes from a population with Lynch syndrome. Whether the same magnitude of benefit applies to sporadic cancers is unknown, though the molecular similarities suggest at least some overlap.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObservational study biases:\u003c\/strong\u003e The 50% reduction seen in observational studies may partly reflect healthy-user bias — people who take aspirin regularly may also engage in other healthy behaviors that reduce cancer risk. This is why the randomized trials are so important.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDespite these limitations, the consistency of the overall picture — with more than 100 observational studies, multiple meta-analyses, and two randomized trials with cancer as a primary endpoint — provides strong evidence that aspirin genuinely reduces cancer risk.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003ePractical Guidance for Patients\u003c\/h2\u003e\n\n\u003cp\u003eIf you are considering daily aspirin for cancer prevention, here are steps to discuss with your healthcare provider:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAssess your personal risk.\u003c\/strong\u003e If you have Lynch syndrome, a family history of colorectal cancer, or other risk factors, the benefit of aspirin is likely to be greater.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGet tested for H. pylori.\u003c\/strong\u003e A simple breath, stool, or endoscopy test can determine if you carry this infection, which increases bleeding risk. Treating it before starting aspirin reduces complications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCheck your blood pressure.\u003c\/strong\u003e Uncontrolled hypertension increases the risk of bleeding in the brain. If your blood pressure is elevated, address that first.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider stomach protection.\u003c\/strong\u003e Ask about a proton pump inhibitor to reduce the risk of gastrointestinal ulcers and bleeding.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChoose the lowest effective dose.\u003c\/strong\u003e While 600mg was used in CAPP2, ongoing research is evaluating whether 100mg provides equal benefit with fewer side effects. Low-dose aspirin (75–100mg) is a reasonable starting point for most people.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonitor with your doctor.\u003c\/strong\u003e Periodic blood counts can detect silent blood loss; ongoing monitoring ensures that risks are caught early.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not stop cardiovascular aspirin without advice.\u003c\/strong\u003e If you already take low-dose aspirin for heart or stroke prevention, do not stop or change your dose without discussing it with your doctor.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIt is important to emphasize that this article is educational and does not replace individualized medical advice. Aspirin is a powerful medication with real risks, and the decision to take it daily should be made in partnership with a healthcare provider who knows your medical history.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eDoes daily aspirin really reduce the risk of colorectal cancer?\u003c\/h3\u003e\n\u003cp\u003eYes. More than 100 observational studies and multiple randomized trials have found that long-term regular aspirin use reduces colorectal cancer risk. After about 4 to 10 years of use, protection becomes apparent. However, the strongest proof comes from people with Lynch syndrome, a rare inherited condition that greatly increases cancer risk.\u003c\/p\u003e\n\u003ch3\u003eWhat is the CaPP3 trial testing?\u003c\/h3\u003e\n\u003cp\u003eCaPP3 is an ongoing trial enrolling 3,000 people who carry Lynch syndrome gene mutations. It compares three daily aspirin doses — 600 mg, 300 mg, and 100 mg — to see whether lower doses work as well as the highest dose for preventing cancer. There is no placebo; everyone receives aspirin. Results were expected around 2020.\u003c\/p\u003e\n\u003ch3\u003eHow much did aspirin lower cancer risk in the CAPP2 trial?\u003c\/h3\u003e\n\u003cp\u003eIn the CAPP2 randomized trial of 1,009 Lynch syndrome carriers, participants who took 600 mg of aspirin daily for at least two years had a greater than 60% reduction in colorectal cancer compared to placebo. The effect appeared from about four years after starting aspirin. Endometrial and other Lynch-related cancers were reduced too.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main risks of taking daily aspirin?\u003c\/h3\u003e\n\u003cp\u003eDaily aspirin raises the risk of gastrointestinal bleeding and ulcers by about 1 extra case per 1,000 people per year. It also increases intracranial hemorrhage risk by about 1 in 10,000 per year. Risks are higher in older people and those with H. pylori infection or high blood pressure. Stomach protection and monitoring can reduce these risks.\u003c\/p\u003e\n\u003ch3\u003eShould I get tested for H. pylori before starting aspirin?\u003c\/h3\u003e\n\u003cp\u003eYes, experts recommend testing for and treating H. pylori infection before regular aspirin use. In people infected with this stomach bacterium, the risk of gastrointestinal bleeding is 2 to 3 times higher. This can be detected with a breath, stool, or endoscopy test, and treating it reduces the chances of bleeding complications.\u003c\/p\u003e\n\u003ch3\u003eWhy did some aspirin trials show no cancer benefit?\u003c\/h3\u003e\n\u003cp\u003eThe Women's Health Study found no cancer reduction during the 10-year trial, but an 18% lower colorectal cancer rate appeared after long-term follow-up up to 18 years. The Physicians' Health Study found no effect. This suggests aspirin's benefit may take many years to appear and may depend on dose, timing, or sex.\u003c\/p\u003e\n\u003ch3\u003eWhat should I discuss with my doctor before taking daily aspirin for cancer prevention?\u003c\/h3\u003e\n\u003cp\u003eAsk about your personal cancer risk, especially if you have Lynch syndrome or a family history. Get an H. pylori test and check your blood pressure. Ask whether a proton pump inhibitor could protect your stomach. Consider starting with low-dose aspirin (75–100 mg daily), but do not stop cardiovascular aspirin without medical advice.\u003c\/p\u003e\n\u003ch3\u003eI have Lynch syndrome. Should I seek a second opinion before deciding whether to take daily aspirin for cancer prevention?\u003c\/h3\u003e\n\u003cp\u003eYes. For Lynch syndrome carriers, daily aspirin has been shown in a randomized trial to reduce colorectal cancer by over 60%, but it carries real risks, including gastrointestinal bleeding and intracranial hemorrhage. A second opinion can help determine whether aspirin is appropriate for your personal risk profile, including testing for H. pylori, checking blood pressure, and considering stomach protection. The optimal dose is still being studied; low-dose aspirin is reasonable, but this decision should be made in partnership with a clinician who knows your history. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article:\u003c\/strong\u003e \"Cancer Prevention with Aspirin: Fact Sheet\" (CAPP3), prepared by Professor Sir John Burn, March 2014.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKey references from the original article:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eKune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illness, operations, medications: case control results from the Melbourne Colorectal Cancer Study. \u003cem\u003eCancer Research\u003c\/em\u003e 1988;48:4399-404.\u003c\/li\u003e\n  \u003cli\u003eBosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. \u003cem\u003eAnnals of Oncology\u003c\/em\u003e 2012;23:1403-15.\u003c\/li\u003e\n  \u003cli\u003eCole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. \u003cem\u003eJ Natl Cancer Inst\u003c\/em\u003e 2009;101:256-66.\u003c\/li\u003e\n  \u003cli\u003eRothwell PM, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. \u003cem\u003eLancet\u003c\/em\u003e 2011;377:31-41.\u003c\/li\u003e\n  \u003cli\u003eRothwell PM, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death. \u003cem\u003eLancet\u003c\/em\u003e 2012;379:1602-12.\u003c\/li\u003e\n  \u003cli\u003eCook NR, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. \u003cem\u003eAnn Intern Med\u003c\/em\u003e 2013;159:77-85.\u003c\/li\u003e\n  \u003cli\u003eBurn J, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. \u003cem\u003eLancet\u003c\/em\u003e 2011;378:2081-7.\u003c\/li\u003e\n  \u003cli\u003eBurn J, et al. Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. \u003cem\u003eN Engl J Med\u003c\/em\u003e 2008;359:2567-78.\u003c\/li\u003e\n  \u003cli\u003eBaigent C, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. \u003cem\u003eLancet\u003c\/em\u003e 2009;373:1849-60.\u003c\/li\u003e\n  \u003cli\u003eGavin DR, et al. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. \u003cem\u003eGut\u003c\/em\u003e 2013;62:242-9.\u003c\/li\u003e\n  \u003cli\u003eRabeneck L, et al. Bleeding and Perforation After Outpatient Colonoscopy and Their Risk Factors in Usual Clinical Practice. \u003cem\u003eGastroenterology\u003c\/em\u003e 2008;135:1899-906.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research and was prepared for educational purposes. It does not constitute medical advice. Always consult a qualified healthcare professional before starting or stopping any medication.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47541991145628,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/it\/products\/aspirin-and-cancer-prevention-what-patients-need-to-know-about-the-evidence-risks-and-new-research","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}